Our laboratory is dedicated to unraveling the complexities of molecular signaling disrupted in triple-negative breast cancer (TNBC). Our primary research focus is on identifying metastasis markers that could serve as potential therapeutic targets for treating TNBC. Additionally, we are investigating the role of gut microbiota in the reduction of both TNBC development and metastasis. 

Epithelial-Mesenchymal Transition (EMT) is a biological process in which epithelial cells transform into mesenchymal stem cells, acquiring migratory and invasive characteristics. EMT plays a vital role in cancer progression and metastasis, particularly in Triple Negative Breast Cancer (TNBC). Our study aims to reduce EMT through various approaches. Current research is investigating epigenetic therapies to reverse EMT in TNBC. Regulating EMT can enhance the effectiveness of chemotherapy and decrease TNBC metastasis.

Recent advancements have underscored the crucial role of gut microbiota in cancer reduction. Various species of gut microbiota can enhance the effectiveness of chemotherapy, immunotherapy, and radiation therapy in combating tumors while mitigating their adverse effects. Gut microbiota exerts their multifaceted impact by modulating diverse immunomodulatory and inflammatory signaling pathways, potentially leading to the suppression of tumor growth. Our study aims to identify the impact of gut microbiota in reducing TNBC development, metastasis and enhancing the effectiveness of anti-cancer treatments.